secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091006
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Q2 net loss $8.2M; cash $5.2M; WM pivotal data expected 2H23
----------------------------------------------------------------------

- Net loss ($8.2M, $0.73/sh) vs ($7.4M, $1.22/sh) in Q2 2022; R&D expense $6.3M, up 40% YoY.
- Cash $5.2M at June 30, 2023, down from $19.9M at Dec 31, 2022; cash runway into Q4 2023.
- WM CLOVER-WaM pivotal top-line data expected 2H23; NDA and 2024 product launch on target.
- Phase 1b in pediatric high-grade gliomas to start Q3 2023; CNSL cohort expanded after complete response.
- Multiple myeloma data: 40-62% response rates in triple-class refractory and post-BCMA patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/0001104659-23-091006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/tm2323620d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer